|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.334 EUR | +1.83% |
|
+7.05% | -16.71% |
| Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
| Mar. 05 | Medicus Pharma Names COO | MT |
Biofrontera AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 17.78 million compared to EUR 15.08 million a year ago. Net loss was EUR 3.15 million compared to EUR 36.75 million a year ago.
Basic loss per share from continuing operations was EUR 0.05. Diluted loss per share from continuing operations was EUR 0.05.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.71% | 22.75M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
BIOFRONTERA AG 
